All News

Sumitomo Dainippon Pharma Announces Positive Topline Results from a Phase 3 Clinical Study of LONASEN, an Atypical Antipsychotic Agent, in the Treatment of Adolescent Patients with Schizophrenia in Japan

Ref: Sumitomo Dainippon

Tags: Press Release Sumitomo Dainippon Schizophrenia and Bipolar Disorder Clinical Research (R&D)Lonasen

Cytokinetics Announces Preclinical Data Relating to CK-3773274 to be Presented at the American Heart Association’s Basic Cardiovascular Sciences Scientific Sessions

Ref: GlobeNewswire

Tags: Press Release Cytokinetics Cardiomyopathies Clinical Research (R&D) Medical Affairs AHA Scientific Sessions CK-3773274

WHO recommends dolutegravir as preferred HIV treatment option in all populations

Ref: WHO

Tags: Press Release AIDS and HIV WHO Regulatory Affairs dolutegravir efavirenz

AbbVie Appoints New General Manager in U.K.

Ref: AbbVie

Tags: People News AbbVie Abbott TAP Pharmaceuticals IPHA Corporate Affairs

IBM gives cancer-killing drug AI project to the open source community

Ref: ZDNet

Tags: NewsPoints IBM Clinical Research (R&D)

ACADIA Pharmaceuticals Announces Top-line Results from Phase 3 ENHANCE Trial of Pimavanserin as Adjunctive Treatment for Patients with Schizophrenia

Ref: Business Wire

Tags: Press Release Acadia Schizophrenia and Bipolar Disorder Clinical Research (R&D)pimavanserin

Forty Seven, Inc. Announces Closing of Underwritten Public Offering and Exercise in Full of Option to Purchase Additional Shares

Ref: GlobeNewswire

Tags: Press Release Forty Seven Corporate Affairs

Gut Microbes May Affect the Course of ALS

Ref: Weizmann Institute of Science

Tags: Press Release Clinical Research (R&D)

Emmaus Life Sciences Receives Notice of Nasdaq Delisting Following Merger with MYnd Analytics

Ref: PR Newswire

Tags: Press Release Emmaus Life Sciences Corporate Affairs Mergers & Acquisitions

Shionogi announces out-licensing agreement with AMR Centre on COT-143, a humanized monoclonal antibody targeting the PcrV protein of Pseudomonas aeruginosa

Ref: Shionogi

Tags: Press Release Shionogi Bacterial Infections Corporate Affairs Licensing COT-143